A trusted resource for modern practices
Aesthetic injectables
Letybo® and Obagi® saypha® bring internationally established injectable platforms to practices looking for differentiated products, practical economics and meaningful support.
Two global stories
The U.S. injectable market is ready for credible alternatives with strong international heritage.
Letybo brings the momentum of Korean aesthetics and a leading global neuromodulator brand. Obagi saypha pairs Austrian-developed hyaluronic acid technology with the recognition of Obagi Medical. Together, they create a focused portfolio built for practices that value quality, differentiation and healthier treatment economics.
The K-Tox conversation
Letybo is the #1 bestselling neuromodulator in South Korea and is approved in more than 65 countries. Its U.S. introduction gives practices a globally trusted option with a distinctly current story.
Austrian HA heritage
Developed by Croma-Pharma and introduced in the U.S. through Obagi Medical, the saypha portfolio brings established European HA expertise to modern aesthetic practices.
Practical solutions, exceptional results
Two globally established injectable stories give practices differentiated options for today’s aesthetic patient.
Practical acquisition costs create more room to build sustainable treatment margins without sacrificing product quality.
ElleVie supports product evaluation, team preparation, launch planning and ongoing account growth.
For licensed healthcare professionals. Product indications, warnings and safety information differ. Refer to each manufacturer’s current prescribing information, directions for use and complete safety information before use.
Ready to evaluate the portfolio?
Talk with ElleVie